LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology, Inc. (NYSE:PBYI), a development stage
biopharmaceutical company, announced the closing of an underwritten
public offering of 1,126,530 shares of its common stock at a price to
the public of $122.50 per share. The shares of common stock issued in
the offering included 146,938 shares of common stock issued upon the
exercise in full by the underwriters of their option to purchase
additional shares. The net proceeds from the offering were approximately
$129.3 million, after deducting the underwriting discount and estimated
offering expenses payable by the Company.
BofA Merrill Lynch, Citigroup and Leerink Partners LLC acted as joint
book-running managers for the offering. Cowen and Company, LLC and UBS
Securities LLC acted as co-managers for the offering.
A registration statement on Form S-3 relating to these securities has
been filed with the Securities and Exchange Commission and declared
effective. The offering of these securities was made only by means of a
written prospectus forming part of the effective registration statement
relating to these securities. Copies of the prospectus for this offering
may be obtained by contacting BofA Merrill Lynch, 222 Broadway, New
York, NY 10038, Attn: Prospectus Department, email: dg.prospectus_requests@baml.com;
Citigroup, c/o Broadridge Financial Solutions, 1155 Long Island Avenue,
Edgewood, NY 11717, phone (800) 831-9146; or Leerink Partners LLC, One
Federal Street, 37th Floor, Boston, MA 02110, Attn: Syndicate
Department, phone (800) 808-7525.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy, nor shall there be any sale of these
securities in any state or other jurisdiction in which such offer,
solicitation or sale would be unlawful prior to registration or
qualification under the securities laws of any such state or other
jurisdiction.
About Puma Biotechnology
Puma Biotechnology, Inc. is a development stage biopharmaceutical
company that acquires and develops innovative products for the treatment
of various forms of cancer. The Company focuses on in-licensing drug
candidates that are undergoing or have already completed initial
clinical testing for the treatment of cancer and then seeks to further
develop those drug candidates for commercial use. The Company is
initially focused on the development of PB272 (oral neratinib), a potent
irreversible tyrosine kinase inhibitor, for the treatment of patients
with HER2 positive metastatic breast cancer and patients with non-small
cell lung cancer, breast cancer and other solid tumors that have a HER2
mutation.
Contact:
Puma Biotechnology, Inc.
Mariann Ohanesian, +1-424-248-6500